This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Amylin Pharmaceuticals, Inc.. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: Rey Halili - Innovator in Mixing Technology
Introduction
Rey Halili is a notable inventor based in San Diego, CA. He has made significant contributions to the field of mixing technology, particularly in the pharmaceutical industry. His innovative approach has led to the development of a unique mixing tool that enhances the efficiency of drug formulation processes.
Latest Patents
Rey Halili holds 1 patent for his invention of a mixing tool. This invention provides devices and methods for mixing a formulation containing two or more constituents, such as a drug product and a diluent. The device features a chamber designed to secure a container of the drug product. Various embodiments of the device are presented, including one with two or more sides connected by a hinge, defining the chamber between them, and a handle for manipulation. Another embodiment includes a housing with side bars that allow visibility of the container from outside, along with a stopping element and a handle with two arms for grasping.
Career Highlights
Rey Halili is currently employed at Amylin Pharmaceuticals, Inc., where he continues to innovate and develop new technologies. His work focuses on improving the processes involved in drug formulation and delivery. His contributions have been instrumental in advancing the capabilities of mixing tools used in the pharmaceutical industry.
Collaborations
Rey collaborates with talented professionals in his field, including Christine Smith and Hong Qi. These collaborations enhance the development of innovative solutions and foster a creative environment for advancing technology.
Conclusion
Rey Halili's work in mixing technology exemplifies the impact of innovation in the pharmaceutical industry. His patent for a mixing tool demonstrates his commitment to improving drug formulation processes. Through his career at Amylin Pharmaceuticals, Inc., he continues to contribute to advancements in this vital field.